关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
9 A- k0 P- F# T' _    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
  Q. O5 V7 Z( E5 p
& V" C  f( O5 M0 d4 o5 ]作者：来自澳大利亚
) _; B8 p4 F/ O1 K' J# Q: F0 u7 n来源：Haematologica. 2011.8.9.
Dear Group,
" y4 V4 u) `$ b) P  e
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
( |5 H2 a$ K1 P3 P. u  nafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
, `, E$ o4 x; x# D
The remarkable news about Sprycel cessation is that all 3 patients had failed
) r! s) `; ]. O4 K* ~2 e% U, oGleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
2 u9 |- U( e9 H$ c9 |5 L; pwho have done well on Gleevec.
; S, c2 ?' ?/ b) w+ R3 i! ]
/ T4 e" A: T. k  k( e; cHopefully, the doctors will report on a larger study and long-term to see if the
* z, {6 J+ L; R1 ~) `response off Sprycel is sustained.

Best Wishes,
Anjana
7 U& a. [& a6 g3 T4 A$ C0 L: s

2 Z2 I' u& A# h& H1 [: V
Haematologica. 2011 Aug 9. [Epub ahead of print]
3 v' f; H2 _7 c% @- eDurable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
' y( K7 u: w3 U! {# ?Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
) T0 c0 E4 [/ @# ^! B  A' |# xSource
Adelaide, Australia;
* e! `6 j1 _0 z) Z" p+ v
. b; Y9 Y; t8 q, j6 A# I6 [* J& RAbstract
/ N7 q6 M- @$ X) QPatients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
9 V& @+ ?5 X0 i" L* y: X* Gresponse have included only patients with a good response to imatinib. We
# \; L$ n2 z" ^1 z, }/ y0 {. i! s8 hdescribe three patients with stable complete molecular response on dasatinib
! S! @4 \  M9 X( Q3 ?0 N. Ytreatment following imatinib failure. Two of the three patients remain in
2 ~* o& J1 c3 P) N0 u9 Bcomplete molecular response more than 12 months after stopping dasatinib. In
2 H) |. T' D% ?these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
- ~6 Y8 A# D: B; y6 ^6 ?4 o" Kimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
' ]6 ?0 K3 p" o" ]" G2 dwho relapsed and in one patient in remission. Our results suggest that the
9 _6 _, r2 M6 ycharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
, Z- U; o$ E  P5 x  h1 ddisease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
( \' l( D" `% y/ I' S: W3 S    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
: a0 H( s& _3 N' r3 T! F
作者：来自法国STIM试验
, H: d6 W2 y$ ]3 p; G来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事